Lincoln Pharmaceuticals Ltd reports 30.50% rise in the Standalone Net Profit at Rs. 17.60 crore in Q3 FY22

• 

Highlights:-•           Net revenues in Q3 FY22 at Rs. 122.52 crore, up 6.18% from Rs. 115.39 crore in Q3 FY21•           Exports (FOB) in 9MFY22 at Rs. 199.78 crore•           Over the last 5 years, company has delivered a robust 20% plus CAGR in profits

                                           Financial Highlights (Standalone)

(Amount in Cr except EPS)

	Q3 FY22	Q3 FY21	Y-O-Y	9M FY22	9M FY21	Y-O-Y
Net Revenue from Operations	122.52	115.39	6.18%	377.64	346.71	8.92%
EBITDA	26.09	20.72	25.90%	86.14	74.97	14.91%
Profit before Tax	23.60	18.43	28.03%	79.17	68.31	15.89%
Net Profit	17.60	13.49	30.50%	58.33	49.68	17.42%
E.P.S (Rs.)	8.79	6.73	30.50%	29.12	24.80	17.42%

Mumbai, February 10, 2022 (GNI):  Lincoln Pharmaceuticals Ltd, one of India’s leading healthcare companies has reported net profit of Rs. 17.60 crore for the Q3 FY22 ended December 2021 as against net profit of Rs. 13.49 crore in the corresponding period last year, growth of 30.50%. Net revenue for the Q3 FY22 was reported at Rs. 122.52 crore, higher by 6.18% over previous fiscal’s same period net revenue of Rs.115.39 crore. Company reported an EBITDA of Rs. 26.09 crore in Q3FY22, a rise of 25.90% as compared to Rs. 20.72 crore in the corresponding period last year. EPS for Q3FY22 was at Rs. 8.79 per share as compared to Rs. 6.73 in the corresponding period last year.

Commenting on the results and performance, Mr. Mahendra Patel, Managing Director, Lincoln Pharmaceuticals Ltd, said, “Company is progressing well on its long-term growth roadmap and we are pleased with the performance so far. Our international business is complementing well with our domestic business to further cement our position in the industry. Progress on the Mehsana expansion for the launch of Cephalosporin products is going as per schedule. Going forward we are confident to improve our growth numbers on all fronts. Strategic growth initiatives, product and geographical expansion, operational efficiency are likely to maximize value for all stakeholders in the near to medium term.” 

Highlights: – 9MFY22 Results

For nine months ended December 2021, company reported net sales of Rs. 377.64 crore, higher by 8.92% over previous fiscal’s same period net sales of Rs. 346.71 crore. Net profit of the company was reported at Rs. 58.33 crore for the nine months ended December 2021 as against net profit of Rs. 49.68 crore in the corresponding period last year, growth of 17.42%. EPS for the 9MFY22 was reported at Rs. 29.12 per share. Exports (FOB) in 9MFY22 at Rs. 199.78 crore.

Over the last 5 years, Lincoln Pharmaceuticals Ltd has delivered a robust 20% plus CAGR in profits and higher single digit growth in sales. The liquidity position of the company is on a strong foundation, supported by healthy cash accruals, no term debt and healthy return ratios. Backed by improvement in the company’s financial risk profile, steady growth in scale & margins, healthy profitability, rating agency ICRA has upgraded the company’s long-term and short-term bank facilities to A and A1 respectively.

Export business of the company has shown remarkable growth in the last few years and had increased to 65% of total sales in FY21 from 11% of total sales in FY13. Company currently exports to 60 plus countries including East & West Africa, Central & Latin America and Southeast Asia. TGA – Australia and EU GMP approvals will further strengthen the company’s presence and expand its network to 90 plus countries. Company looks to enter the EU markets during the current financial year, stated in the press release.

Lincoln Pharma has a state-of-the-art manufacturing facility unit at Khatraj in Ahmedabad, Gujarat, complying with stringent international quality and compliance norms and certified by EUGMP, WHO-GMP, TGA – Australia and ISO-9001: 2015. Company has developed 600 plus formulations in 15 therapeutic areas and has a strong product/brand portfolio in anti-infective, respiratory system, gynaecology, cardio & CNS, anti-bacterial, ant-diabetic, anti-malaria among others. To complement the company’s strong presence in the acute segment, company is also building a portfolio in lifestyle and chronic segments, especially dermatology, gastro and pain management. Company has filed 25 plus patent applications and is awarded with seven patents. Company has a strong presence in the domestic market nationally with a dedicated field force of over 600 personnel who cater to more than 30,000 doctors, chemists across the country.enfs